Adults With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab for Over 1 Year Achieve Optimal Treatment Response by Patient-Reported Outcomes

Objective: To assess the proportion of adults with moderate-to-severe atopic dermatitis treated with dupilumab monotherapy who achieved a continued minimal disease activity over time (as measured by the achievement of individual patient-reported outcome targets). Introduction: Achieving and maintaining minimal symptoms and disease impact are important goals for patients with atopic dermatitis (AD). We assessed the proportion of adults with moderate-to-severe AD receiving dupilumab monotherapy who achieved minimal disease activity over time as measured by patient-reported outcome (PRO) instruments. Methods: Adults with moderate-to-severe AD achieving Investigator’s Global Assessment (IGA)=0/1 and/or Eczema Area and Severity Index-75 (EASI-75) after 16 weeks of dupilumab 300 mg every two weeks (q2w) monotherapy in LIBERTY AD SOLO 1/2 (n=199; NCT02277743, NCT02277769) were re-randomized for 36 additional weeks to placebo or dupilumab 300 mg q2w, every 4 weeks (q4w), or every 8 weeks (q8w) in SOLO-CONTINUE (NCT02395133). The proportion of patients achieving optimal results in each PRO (Dermatology Life Quality Index [DLQI]=0–1, Patient Global Assessment of Disease Status [PGADS]=very good/excellent, Patient Global Assessment of Treatment Effect [PGATE]=very good/excellent, total Patient-Oriented Eczema Measure [POEM]=0–2) at the end of SOLO 1/2 and the end of SOLO-CONTINUE are reported. Patients who discontinued or received systemic rescue were set to non-responders; missing values were addressed through multiple imputation regardless of rescue treatment. Results: Among re-randomized patients (responders) in SOLO-CONTINUE, proportions achieving target endpoints at both Week 16 and Week 52 were higher with active dupilumab dosing than placebo across measures. DLQI: dupilumab q2w 66%, q4w 72%, q8w 61%, placebo 7%. PGADS: dupilumab q2w 75%, q4w 68%, q8w 50%, placebo 22%. PGATE: dupilumab q2w 80%, q4w 79%, q8w 49%, placebo 26%. POEM: dupilumab q2w 73%, q4w 75%, q8w 38%, placebo 11%. Safety was consistent with the known safety profile. Conclusions: Most responder patients at Week 16 achieved and maintained minimal disease activity according to PROs at Week 52 with q2w and q4w dupilumab monotherapy maintenance dosing. Acknowledgments and Funding Sources: Data included in this abstract were originally presented at the 84th Annual Meeting of the American Academy of Dermatology (AAD); Denver, CO, USA; March 27–31, 2026. Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. ClinicalTrials.gov Identifiers: NCT02277743, NCT02277769, NCT02395133. Medical writing/editorial assistance was provided by Jacqueline Moy, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice guidelines.